Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
April 26, 2023 10:00 ET
|
ZENTALIS PHARMACEUTICALS
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for...
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
April 17, 2023 09:00 ET
|
ZENTALIS PHARMACEUTICALS
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy...
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
March 01, 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
On track to declare monotherapy RP2D for potentially first-in-class/best-in-class Wee1 inhibitor, azenosertib (ZN-c3), and provide program updates and potential paths to registration in 1H 2023 ...
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
February 13, 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2023 17:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
February 01, 2023 07:01 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2023 17:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022 17:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- ZentalisTM Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
November 09, 2022 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from...
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
November 08, 2022 07:01 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...